Experience in using dipyridamole in the group of pregnant women with a high risk of perinatal pathology
https://doi.org/10.21518/2079-701X-2018-7-98-100
Abstract
This article provides the evaluation results of the efficacy of low-dose dipyridamole (CurantylÒ) [1, 2] taken to prevent placental insufficiency in women in the group with a high risk of perinatal pathology and feto-maternal disease in past medical history. The early use of low-dose dipyridamole in high-risk groups contributes to a significant reduction in the frequency of intrauterine growth retardation, premature labour and birth of low birth-weight babies.
About the Authors
T. M. Sokolova
Novosibirsk State Medical University of the Ministry of Health of Russia
Russian Federation
MD
Russian Federation
MD
I. O. Marinkin
Novosibirsk State Medical University of the Ministry of Health of Russia
Russian Federation
MD, Prof
Russian Federation
MD, Prof
V. M. Kuleshov
Novosibirsk State Medical University of the Ministry of Health of Russia
Russian Federation
MD
Russian Federation
MD
K. Yu. Makarov
Novosibirsk State Medical University of the Ministry of Health of Russia
Russian Federation
MD
Russian Federation
MD
References
1. Curantyl No. 25. Patient Information Leaflet. Electronic resource: http://grls.rosminzdrav.ru. Accessed date: 09.19.2016.
2. Nesterova EA, Putilova NV. The role of parental-fetal thrombophilia in the development of severe placental insufficiency. Akusherstvo i Ginekologiya, 2014, 12: 5-9.
3. Duffett L, Rodger M. LMWH to prevent placenta-mediated pregnancy complications: an update. Br J Haematol, 2015 Mar, 168(5): 619-638.
4. Kozak YuV, Kiseleva TV, Makarov KYu, Kim VL. Evaluation of the effectiveness of managing pyelo-nephritis in pregnant women using ultraviolet blood irradiation. Meditsina i Obrazovanie v Sibiri, 2014, 6: 10-14.
5. Unanyan AL, Arakelov SE, Polonskaya LS, Guriev TD, Ilyicheva TS, Baburin DV, Kossovich Yu.M. Placental insufficiency: peculiarities of etiopathogenesis, therapy and prevention. Consilium Medicum, 2015, 17 (6): 37-40.
6. Obstetrics: national leadership. Ed. G.M. Savelieva, G.T. Sukhikh, V.N. Serova, V.E. Radzinsky. 2 nd ed., Revised. and additional. M., 2016, 1104 p.
7. Korteweg FJ, Erwich JJ, Holm JP, Ravisé JM, Meer van der J, Veeger NJ et al. Diverse placental pathologies as the main causes of fetal death. Obstet. Gynecol, 2009, 4: 809-817.
8. Cox P, Marton T. Pathological assessment of intrauterine growth restriction. Best Pract Res. Clin. Obstet. Gynaecol, 2009, 23(6): 751-764. doi: 10.1371/journal. pone.0077748.
9. Makatsariya AD, Bitsadze VO, Khizroeva DKh, Khamani NM. Placental insufficiency in complicated pregnancy and therapeutic potential of dipyridamole. Akusherstvo, Ginekologiya i Reproduktsiya, 2016, 4: 72-82.
10. Shilyaeva NS, Maksimova YuV, Makarov KYu. Changes in blood pressure during pregnancy. Meditsina i Obrazovanie v Sibiri, 2008, 5: 11-13.
11. Schleussner E, Kamin G, Seliger G, Rogenhofer N, Ebner S, Toth B et al. Low-molecular-weight heparin for women with unexplained recurrent pregnancy loss: a multicentre trial with a minimization rand-omization scheme. Ann. Intern. Med, 2015, 162(9): 601-609. doi: 10.7326/M14-2062.
12. De Jong PG, Kaandorp S, Di Nisio M, Goddijn M, Middeldorp S. Aspirin and/or heparin for women with unexplained recurrent miscarriage with or without inherited thrombophilia. Cochrane Database Syst. Rev, 2014, 7: CD004734. doi: 10.1002/14651858.CD004734.pub4.
13. Dodd JM, McLeod A, Windrim RC, Kingdom J. Antithrombotic therapy for improving maternal or infant health outcomes in women considered at risk of placental dysfunction. Cochrane Database Syst. Rev, 2013, 7: CD006780. doi: 10.1002/14651858.CD006780.pub2.
14. Bates SM et al. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest, 2012, 141(2 Suppl.): 691– 736. doi: 10.1378/chest.11-2300.
15. Yakimova AV, Makarov KYu, Sokolova TM. Antithrombotic therapy as a way of improving perinatal outcomes in women with placental insufficiency (literature review). Effektivnaya Farmakoterapiya, 2015, 5: 6-10.
16. Akinshina SV, Bitsadze VO, Makatsaria AD. Clinical rational for the use of dipyridamole in obstetric practice. Akusherstvo, Ginekologiya i Reproduktsiya, 2017, 11 (2): 45-48.
Review
For citations:
Sokolova TM, Marinkin IO, Kuleshov VM, Makarov KY. Experience in using dipyridamole in the group of pregnant women with a high risk of perinatal pathology. Meditsinskiy sovet = Medical Council. 2018;(7):98-100. (In Russ.) https://doi.org/10.21518/2079-701X-2018-7-98-100
Views:
862
Email this article 